GlassScriptPhysician profile
Melda Isaac
NPI 1053356667
$3,772.29
in general payments reported to CMS, 2019-2025
19 companies · $487 in 2025
The $487 reported for 2025 was more than what 78% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $569 · 2022: $1,185 · 2023: $877 · 2024: $654 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,735 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,735.06 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $283.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,204.13 | 2021-2022 | |
| Merz North America, INC. | $1,009.32 | 2021-2025 | Xeomin |
| Abbvie INC. | $412.65 | 2022-2025 | |
| Journey Medical Corporation | $194.93 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $162.68 | 2021-2025 | Winlevi, Absorica Ld |
| Galderma Laboratories, L.P. | $116.58 | 2022-2023 | Aklief, Epsolay, Twyneo |
| Strata Skin Sciences, INC. | $84.40 | 2022 | |
| Pfizer INC. | $82.05 | 2022-2023 | |
| Incyte Corporation | $69.08 | 2023-2025 | Opzelura |
| Revance Therapeutics, INC. | $69.07 | 2024-2025 | Daxxify |
| Amgen INC. | $67.41 | 2022-2024 | Otezla, Enbrel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.60 | 2024 | Spevigo |
| Almirall LLC | $52.73 | 2021-2024 | Klisyri |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $42.06 | 2023-2024 | Jublia, Arazlo, Cabtreo |
| Solta Medical, A Division of Bausch Health US, LLC | $36.41 | 2023-2024 | Fraxel |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $36.24 | 2022-2023 | Simponi Aria, Simponi, Stelara |
| Genzyme Corporation | $31.02 | 2025 | |
| Mayne Pharma Commercial LLC | $22.00 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $21.93 | 2024 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melda Isaac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.